Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 3
2(28.6%)
7Total
N/A(5)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06373601Not ApplicableRecruiting

SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

Role: lead

NCT05471245Not ApplicableCompleted

AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

Role: lead

NCT03399994Not ApplicableCompleted

Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES

Role: lead

NCT00944333Phase 3Terminated

Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy

Role: lead

NCT01086579Not ApplicableUnknown

Balloon Elution and Late Loss Optimization (BELLO) Study

Role: lead

NCT00936169Not ApplicableCompleted

Angiography Versus (vs) IVUS Optimisation

Role: lead

NCT00638976Phase 3Completed

INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

Role: lead

All 7 trials loaded